热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　维升药业-B（02561）午前股价上涨3.08%，现报44.80港元，成交额104.211万港元。

　　根据维升药业招股书，公司研发进展最快的是隆培促生长素（长效生长激素），公司预计在2025下半年国内获批上市，有望成为国内第三款上市的长效生长激素。目前，公司拥有2款独特品种，分别为那韦培肽和帕罗培特立帕肽，后者有望在2025年底递交上市申请，据悉，今年6月，维升药业与药明生物达成合作，推进本地化生产，努力以价优高值的产品满足国内患者临床需求。今年7月，维升又与安科生物达成合作，共同推进产品的商业化，未来市场前景值得期待。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.